Beginner-friendly– category –

Introduction: Why Are Bispecific Antibody Drugs Gaining Attention? In recent years, bispecific antibody drugs (BsAbs) have garnered increasing attention in the treatment of cancer, autoimmune diseases, and infectious diseases. By binding...

Global Strategies Shaping the Future of in vivo CAR-T Development Throughout this series, we have explored the cutting-edge developments of in vivo CAR-T therapy in an accessible way for beginners. In this final installment, we will exam...

Key Figures Shaping the Future of in vivo CAR-T This series aims to provide a clear and accessible overview of the latest advancements in in vivo CAR-T therapies, especially for beginners. In Part 7, we focus on the global researchers, e...

In vivo CAR-T therapy has rapidly emerged as a promising next-generation cancer treatment. However, realizing its full potential requires overcoming several hurdles: targeting only the desired cells, ensuring safety, and maintaining sust...

In previous installments, we've explored the fundamentals of CAR-T, the features of the in vivo model, gene delivery strategies, target antigens, and intracellular signaling. In this fifth edition, we shift our focus to clinical applicat...

For in vivo CAR-T cells to attack cancer persistently and effectively, the structure of the CAR itself is critical. In particular, the design of co-stimulatory molecules and intracellular signaling domains directly impacts the treatment'...

In this third installment of our introductory series on in vivo CAR-T, we focus on a vital component for realizing safe and effective therapy: the design of CAR expression. We explore how “smart control” of CAR expression—targeting tumor...

In the first installment of our series, we introduced the revolutionary CAR-T cell therapy through the moving story of Emily Whitehead. This time, we take a deep dive into the underlying technologies that make “in vivo CAR-T” possible. F...

CAR-T cell therapy has emerged as a groundbreaking treatment that specifically targets cancer cells. Among its forms, the “in vivo type” CAR-T—where the therapeutic process happens inside the body—is gaining attention as a next-generatio...

Over the past few years, the landscape of Antibody-Drug Conjugates (ADCs) has undergone a dramatic transformation, shifting from a niche therapeutic approach to a central pillar of oncology innovation. This bonus chapter highlights recen...

Antibody-drug conjugates (ADCs) deliver highly potent cytotoxic agents specifically to cancer cells, representing a breakthrough in targeted therapy. This article explains the final stage of ADC function—how the linker system releases th...

In Antibody-Drug Conjugates (ADCs), antibodies serve as targeting agents that deliver drugs to cancer cells. This article focuses on the "Variable Region," the key structure that enables antibodies to specifically recognize cancer antige...

Antibody-drug conjugates (ADCs) are next-generation therapeutics gaining attention, especially in oncology. In this second part, we introduce the three fundamental components of ADCs—antibody, linker, and payload—explaining their functio...

Summer Special｜Beginner-Friendly Intro Series Vol.2 (Part 1)What Are Antibodies? The Origin Story of ADCs – A Precision Cancer Weapon Welcome to Part 1 of our Summer Special Beginner Series Vol.2 on Morningglorysciences.This time, we’ll...

Summer Special｜Beginner-Friendly Intro Series Vol.1 (Part 2)Are They Safe? Global Competition and the Future of Anti-Obesity Drugs In Part 1, we explored what anti-obesity medications are, how GLP-1 works, and the key players in the cur...

Summer Special｜Beginner-Friendly Intro Series Vol.1 (Part 1)What Are Slimming Drugs? A Gentle Introduction to Anti-Obesity Medications Welcome to the Morningglorysciences Summer Special Beginner Series!This series is designed for reader...